Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Koninklijke Philips N.V (1PHIA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Koninklijke Philips N.V €11.46, price €21.19, upside -45.9%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
KP
Broad data
Oct 2, 2026
Koninklijke Philips N.V
1PHIA · MIStretched ValuationStrong overvaluation with only moderate quality.
!Fair value €11.46 · Strongly overvalued (−45.9%)
!Quality 57/100
!Weak Growth (revenue 3y +0.0 %/yr)
!Thin margins · 5.5% net margin (TTM)
✓Moderate debt · generates free cash flow
!4.0% dividend yield · Watch coverage
!Narrow moat 37/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range €9.92 – €32.95 · fair‑value band €6.24 – €18.48 · the €21.19 price screens above the €11.46 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Company profile
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.
Show more
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Stock analysis
Koninklijke Philips N.V (1PHIA) currently trades at €21.19, while our model-based Fair Value estimate is €11.46, 45.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €16.03 per share, and 3 of the 24 models we run sit above the €21.19 price.
Bear case: the Dividend Discount group reads lowest at €3.39, and 21 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €6.24 (bear) to €18.48 (bull), the price of €21.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Koninklijke Philips N.V reported revenue of €17.8B in FY2025 versus €17.8B in FY2022, a compound +0.0%/yr. Reported net income was €895M in FY2025.
Key figures
Market cap €23.6B · P/E ratio 21.0 · P/S ratio 1.05 · EPS (TTM) €1.01 · Dividend yield 4.0% · Net margin 5.0% · Return on equity 8.4% · Return on assets (EBIT) 1.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −46%, 1PHIA screens richer than that median.
Fair Value models
Bear €6.24
Fair Value €11.46
Bull €18.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.1210 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€4.01
€6.90
€12.25
74
Growth DCF
€4.35
€7.15
€11.95
73
Residual Income
€9.57
€10.32
€11.49
73
All 24 models by family
DCF Models
FCF DCF
€4.01
€6.90
€12.25
74
Owner Earnings
€12.48
€18.69
€30.20
72
5Y Revenue Exit
€7.13
€12.91
€21.35
67
5Y EBITDA Exit
€14.10
€24.99
€39.41
70
5Y P/E Exit
€7.47
€13.51
€20.72
66
10Y Revenue Exit
€5.49
€9.69
€14.30
63
10Y EBITDA Exit
€10.08
€17.16
€24.90
65
10Y P/E Exit
€6.05
€10.06
€13.93
61
Earnings-Based
Graham-Dodd
€6.26
€7.65
€8.61
65
EPV
€7.86
€9.73
€11.37
71
Dividend Discount
Gordon GGM
€3.10
€3.39
€3.84
67
DDM Multi-Stage
€3.10
€3.89
€4.99
65
Multiples
P/E Multiple
€15.19
€20.26
€25.32
63
P/S Multiple
€11.74
€15.65
€19.57
58
P/B Multiple
€11.74
€15.65
€19.57
55
EV/EBIT
€15.65
€21.99
€28.32
65
EV/EBITDA
€24.44
€33.71
€42.97
67
EV/Revenue
€10.21
€16.03
€21.84
53
Asset-Based
NCAV (Graham)
€5.64
€7.55
€11.27
54
Growth DCF
Growth DCF
€4.35
€7.15
€11.95
73
Rev-Margin DCF
€7.13
€13.09
€20.29
68
Economic Profit
Residual Income
€9.57
€10.32
€11.49
73
ROIC Compounder
€7.86
€9.73
€11.40
69
Growth Earnings
Growth-Adj P/E
€10.71
€15.30
€19.89
65
Notify me when 1PHIA reaches fair value
Put 1PHIA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
57/100
Of which business quality 53 · Market factors (momentum, volatility) 37
Profitability
40
Margins and returns on capital today
Quality Growth
63
Are margins and returns improving?
Cashflow
32
Earnings quality: real cash, not paper profit
Fin. Strength
48
Balance sheet, leverage, solvency risk
Investment
97
Disciplined investing over empire-building
Low Volatility
69
Calm price path (market factor)
Momentum
30
Price trend over the last 3–12 months (market factor)
52W Momentum
13
Distance to the 52-week high (market factor)
Net Issuance
68
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.0% (2022) → 8.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +27.8% a year for the price and +1.2% for the forecasts.
Forecast 2026 (sales)+0.9%
Forecast 2027 (sales)+4.5%
Projected 2028 (sales)+4.2%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.6%
1PHIA screens overvalued: fair value 46% below the price. Compare with Abbott Laboratories, →
Compare Koninklijke Philips N.V with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| STERIS plc STE | $208.93 | $229.82 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Koninklijke Philips N.V (1PHIA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of €11.46 versus a price of €21.19, about −46% upside (overvalued).
What is the fair value of 1PHIA?
Our model-based fair value for Koninklijke Philips N.V is €11.46 (as of Oct 2, 2026), built from audited fundamentals. The current price: €21.19.
What is the quality score of 1PHIA?
Koninklijke Philips N.V has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Koninklijke Philips N.V (1PHIA)?
Our model-based price target is the fair value of €11.46 (as of Oct 2, 2026) from 24 valuation models. Cautious scenario €6.24, optimistic scenario €18.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Koninklijke Philips N.V stock forecast for 2026?
Our models put fair value at €11.46, about −46% upside versus a price of €21.19 (overvalued). Cautious scenario €6.24, optimistic scenario €18.48. The calculation is refreshed regularly with new filings.
What is the revenue of Koninklijke Philips N.V (1PHIA)?
Koninklijke Philips N.V reported trailing-twelve-month revenue of about €17.6B (latest available figure, as of Oct 2, 2026).
Does Koninklijke Philips N.V pay a dividend?
Koninklijke Philips N.V currently shows a dividend yield of about 4.01% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Koninklijke Philips N.V (1PHIA)?
For today's price to be fair in a discounted-cash-flow model, Koninklijke Philips N.V would have to grow free cash flow by +30.6 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +0.0 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 1PHIA use?
Our models discount Koninklijke Philips N.V at 11.3 %: a base by market capitalisation (large), damped by beta 0.93, country premium for Italy. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Koninklijke Philips N.V that is +30.6 % per year a year over ten years, using the same discount rate (11.3 %) and the same formula as our fair value.
How much growth has Koninklijke Philips N.V (1PHIA) delivered so far?
Over the past 3 years revenue at Koninklijke Philips N.V grew +0.0 % a year. The price currently implies +30.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Koninklijke Philips N.V (1PHIA) growing?
The median revenue growth in the sector is +9.7 % a year. That is the yardstick for the growth priced into Koninklijke Philips N.V (+30.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Koninklijke Philips N.V (1PHIA)?
The free-cash-flow yield on the price is 2.50 %: that much free cash flow Koninklijke Philips N.V produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Koninklijke Philips N.V (1PHIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Koninklijke Philips N.V it is €11.46 per share (as of Oct 2, 2026), against a price of €21.19. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Koninklijke Philips N.V stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 1PHIA trades above its calculated fair value: price €21.19, fair value €11.46, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1PHIA?
No. The price is what the market pays today (€21.19); the fair value is what the company's own numbers justify (€11.46). For Koninklijke Philips N.V the two are €9.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Koninklijke Philips N.V worth?
The market values Koninklijke Philips N.V at about €23.6B (market capitalisation, as of Oct 2, 2026). Per share that is €21.19; our models calculate a fair value of €11.46 per share.
What do the bullish and bearish scenarios say about 1PHIA?
Our models span a range for Koninklijke Philips N.V: cautious scenario €6.24, base €11.46, optimistic €18.48 per share (as of Oct 2, 2026, price €21.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 1PHIA from its 52-week high?
Koninklijke Philips N.V trades at €21.19, about 20% below its 52-week high of €26.65 and at the low of €21.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €11.46 is for.
Which stocks are comparable to Koninklijke Philips N.V?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Koninklijke Philips N.V stock attractive at the current price?
The data as of Oct 2, 2026: price €21.19, calculated fair value €11.46 (−46%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1PHIA calculated?
We run Koninklijke Philips N.V through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €11.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Koninklijke Philips N.V itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Koninklijke Philips N.V (1PHIA)?
The closing price on Oct 2, 2026 was €21.19. Our model-based fair value is €11.46, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Koninklijke Philips N.V right now?
The price sits above even our optimistic bull case (€18.48). The favourable scenario is already priced in. The model range is unusually wide (€6.24 to €18.48). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Koninklijke Philips N.V
How large is the market capitalisation of Koninklijke Philips N.V (1PHIA)?
The market capitalisation of Koninklijke Philips N.V is €23.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Koninklijke Philips N.V (1PHIA)?
The price-to-earnings ratio of Koninklijke Philips N.V is 21.0. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Koninklijke Philips N.V (1PHIA)?
The price-to-sales ratio of Koninklijke Philips N.V is 1.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Koninklijke Philips N.V (1PHIA)?
Earnings per share at Koninklijke Philips N.V are €1.01 (price ÷ EPS = P/E 21.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Koninklijke Philips N.V (1PHIA)?
The dividend yield of Koninklijke Philips N.V is 4.0% (payout 84.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Koninklijke Philips N.V (1PHIA)?
The net margin of Koninklijke Philips N.V is 5.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Koninklijke Philips N.V (1PHIA)?
The return on equity (ROE) of Koninklijke Philips N.V is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Koninklijke Philips N.V (1PHIA)?
On an EBIT basis the return on assets of Koninklijke Philips N.V is 1.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Koninklijke Philips N.V (1PHIA)?
The operating margin of Koninklijke Philips N.V is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Koninklijke Philips N.V (1PHIA)?
Revenue at Koninklijke Philips N.V is growing −4.7% versus a year earlier (3y avg +0.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Koninklijke Philips N.V (1PHIA)?
Earnings per share at Koninklijke Philips N.V are growing +97.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Koninklijke Philips N.V (1PHIA) carry?
The net debt of Koninklijke Philips N.V is €4.1B (fiscal year 2025, ≈ 8.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.